Response assessment in lymphoma relies on imaging scans that do not capture biologic
processes at the molecular level. Monitoring circulating tumor DNA (ctDNA) with next …

Opinion statement The goal of therapy for aggressive B-cell lymphomas such as diffuse
large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) is to achieve cure. Combination …

Background The prognostic value of aberrant DNA methylation of cell-free circulating DNA
in plasma has not previously been evaluated in diffuse large B cell lymphoma (DLBCL). The …

Circulating free nucleic acids; cell free DNA and circulating micro-RNA, are found in the
plasma of patients with hematologic and solid malignancies at levels higher than that of …

In 1948, Mandel and Métais detected nucleic acids in peripheral blood plasma, thereby
invalidating the previous dogma claiming that DNA is always cell-bound. 1 However, long …

The ability to precisely monitor the effectiveness of therapy for non-Hodgkin lymphoma has
important clinical implications. In patients with curable lymphomas, such as diffuse large B …

ABSTRACT Next Generation Sequencing (NGS) has redefined the genetic landscape of
Diffuse Large B-Cell Lymphoma (DLBCL) by identifying recurrent somatic mutations …

First introduced to biomedical research in 1980, the term biomarker has taken on a life of its
own in recent years and has come to mean a number of things. In biomedical science …

Detection and determination of tumor biomarkers are made from tissue and blood collection.
During the last decade new biological sources are feasible: circulating tumor cells and …

In this review, Drs. Melani and Roschewski discuss the current state of molecular-based
prediction of outcomes and monitoring of patients with lymphoma before, during, and after …